
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYPREXA | CHEPLAPHARM Arzneimittel | N-021253 RX | 2004-03-29 | 1 products, RLD, RS |
| ZYPREXA | CHEPLAPHARM Arzneimittel | N-020592 RX | 1996-09-30 | 6 products, RLD |
| ZYPREXA ZYDIS | CHEPLAPHARM Arzneimittel | N-021086 RX | 2000-04-06 | 4 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYPREXA RELPREVV | CHEPLAPHARM Arzneimittel | N-022173 RX | 2009-12-11 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| lybalvi | New Drug Application | 2025-02-28 |
| olanzapine | ANDA | 2025-09-20 |
| olanzapine and fluoxetine | ANDA | 2025-03-27 |
| symbyax | New Drug Application | 2025-01-22 |
| zyprexa | New Drug Application | 2025-07-25 |
| zyprexa zyprexa | New Drug Application | 2025-01-08 |
| zyprexa zyprexa | New Drug Application | 2025-01-30 |
Expiration | Code | ||
|---|---|---|---|
OLANZAPINE / SAMIDORPHAN L-MALATE, LYBALVI, ALKERMES INC | |||
| 2026-05-28 | NCE | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Olanzapine / Samidorphan L-Malate, Lybalvi, Alkermes Inc | |||
| 11707466 | 2041-11-12 | DP | |
| 8778960 | 2032-02-13 | U-3136, U-3137 | |
| 9119848 | 2031-08-30 | DP | |
| 9126977 | 2031-08-23 | DP | U-3136, U-3137 |
| 9517235 | 2031-08-23 | U-3138, U-3139 | |
| 10300054 | 2031-08-23 | DP | U-3140, U-3141 |
| 10716785 | 2031-08-23 | U-3136, U-3137 | |
| 11185541 | 2031-08-23 | U-3140 | |
| 11241425 | 2031-08-23 | U-3137 | |
| 11351166 | 2031-08-23 | U-3140, U-3141 | |
| 11793805 | 2031-08-23 | U-3734 | |
| 7262298 | 2025-11-23 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 2 | 8 | — | — | 11 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | 4 | — | — | 5 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 2 | — | — | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Olanzapine |
| INN | olanzapine |
| Description | Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.
|
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1 |
| PDB | — |
| CAS-ID | 132539-06-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL715 |
| ChEBI ID | 7735 |
| PubChem CID | 4585 |
| DrugBank | DB00334 |
| UNII ID | N7U69T4SZR (ChemIDplus, GSRS) |











